Colorectal cancer (advanced) - irinotecan, oxaliplatin & raltitrexed (replaced by TA93)
The clinical effectiveness and cost effectiveness of irinotecan, oxaliplatin and raltitrexed for colorectal cancer
Summary
This guidance has been replaced by TA93 Colorectal cancer (advanced) – irinotecan, oxaliplatin and raltitrexed (review)
Guidance documents
Implementing this guidance
Other information
About this guidance
Technology appraisals TA33
Issued: March 2002
How this guidance was produced